PubRank
Search
About
A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer
Clinical Trial ID NCT01804465
PubWeight™ 22.12
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT01804465
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
Oncoimmunology
2014
1.22
2
Trial watch: Dendritic cell-based interventions for cancer therapy.
Oncoimmunology
2013
1.09
3
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
Oncoimmunology
2015
1.06
4
Molecular pathways and targets in prostate cancer.
Oncotarget
2014
1.00
5
Clinical impact of checkpoint inhibitors as novel cancer therapies.
Drugs
2014
0.99
6
Cancer immunotherapy in clinical practice -- the past, present, and future.
Chin J Cancer
2014
0.98
7
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.
Front Immunol
2014
0.92
8
AR function in promoting metastatic prostate cancer.
Cancer Metastasis Rev
2014
0.91
9
Trial watch: Dendritic cell-based anticancer therapy.
Oncoimmunology
2014
0.90
10
Immunotherapy for prostate cancer: recent developments and future challenges.
Cancer Metastasis Rev
2014
0.90
11
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.
Int J Mol Sci
2013
0.88
12
Immunotherapy for solid tumors--a review for surgeons.
J Surg Res
2013
0.83
13
Improving the clinical impact of biomaterials in cancer immunotherapy.
Oncotarget
2016
0.83
14
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
Cancer Immunol Immunother
2015
0.82
15
Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.
Core Evid
2014
0.81
16
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Immunotherapy
2014
0.81
17
New drugs in prostate cancer.
Prostate Int
2016
0.80
18
Immunobiology and immunotherapy in genitourinary malignancies.
Ann Transl Med
2016
0.78
19
Immunotherapy for prostate cancer: False promises or true hope?
Cancer
2016
0.78
20
The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.
Rev Urol
2014
0.77
21
Immune Therapy for Prostate Cancer.
Cancer J
2016
0.76
22
Immunotherapy in genitourinary malignancies.
Curr Opin Urol
2016
0.75
23
Evaluating immune responses after sipuleucel-T therapy.
Cancer Biol Ther
2015
0.75
24
A Perspective of Immunotherapy for Prostate Cancer.
Cancers (Basel)
2016
0.75
25
Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options.
P T
2014
0.75
26
Immune Checkpoint Therapies in Prostate Cancer.
Cancer J
2016
0.75
Next 100